Robin Sanderson

1.4k total citations
28 papers, 315 citations indexed

About

Robin Sanderson is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Robin Sanderson has authored 28 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 8 papers in Pathology and Forensic Medicine and 7 papers in Immunology. Recurrent topics in Robin Sanderson's work include CAR-T cell therapy research (24 papers), Lymphoma Diagnosis and Treatment (8 papers) and Biosimilars and Bioanalytical Methods (6 papers). Robin Sanderson is often cited by papers focused on CAR-T cell therapy research (24 papers), Lymphoma Diagnosis and Treatment (8 papers) and Biosimilars and Bioanalytical Methods (6 papers). Robin Sanderson collaborates with scholars based in United Kingdom, United States and Germany. Robin Sanderson's co-authors include Andrea Kühnl, Sarah Thomas, Julie Gibbs, Maeve O’Reilly, Claire Roddie, Amy A. Kirkwood, Maria A. V. Marzolini, Wendy Osborne, Sunil Iyengar and William Townsend and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Radiology.

In The Last Decade

Robin Sanderson

24 papers receiving 313 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robin Sanderson United Kingdom 9 229 84 74 52 47 28 315
Núria Martínez‐Cibrián Spain 9 189 0.8× 45 0.5× 52 0.7× 44 0.8× 46 1.0× 23 286
Matthew L. Ulrickson United States 8 313 1.4× 156 1.9× 53 0.7× 77 1.5× 66 1.4× 35 401
Maria A. V. Marzolini United Kingdom 9 229 1.0× 84 1.0× 57 0.8× 68 1.3× 61 1.3× 21 310
Ana Cordeiro Brazil 5 332 1.4× 30 0.4× 80 1.1× 56 1.1× 89 1.9× 21 400
Monalisa Ghosh United States 9 170 0.7× 46 0.5× 49 0.7× 87 1.7× 26 0.6× 45 308
Patricia Steinert United States 6 178 0.8× 24 0.3× 51 0.7× 48 0.9× 43 0.9× 19 250
Viktoria Blumenberg Germany 10 304 1.3× 46 0.5× 85 1.1× 61 1.2× 72 1.5× 32 361
Kathleen Ruehle United States 8 212 0.9× 41 0.5× 27 0.4× 78 1.5× 30 0.6× 24 291
Xiaolu Long China 9 133 0.6× 41 0.5× 23 0.3× 75 1.4× 31 0.7× 22 233

Countries citing papers authored by Robin Sanderson

Since Specialization
Citations

This map shows the geographic impact of Robin Sanderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Sanderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Sanderson more than expected).

Fields of papers citing papers by Robin Sanderson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Sanderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Sanderson. The network helps show where Robin Sanderson may publish in the future.

Co-authorship network of co-authors of Robin Sanderson

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Sanderson. A scholar is included among the top collaborators of Robin Sanderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Sanderson. Robin Sanderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sanderson, Robin, Jane E. Norman, Joht Singh Chandan, et al.. (2025). CAR T access and outcomes in large B‐cell lymphoma according to ethnicity and socioeconomic deprivation in the UK. British Journal of Haematology. 206(4). 1178–1185. 1 indexed citations
2.
O’Reilly, Maeve, Lorna Neill, Simon M. Collin, et al.. (2024). High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T‐cell therapy for large B‐cell lymphoma. HemaSphere. 8(1). e29–e29. 5 indexed citations
3.
Sanderson, Robin, et al.. (2023). The nutritional impact of CD19‐targeted CAR‐T therapy versus BEAM chemotherapy for adult patients with lymphoma. Journal of Human Nutrition and Dietetics. 36(5). 2099–2107.
4.
Roddie, Claire, Lorna Neill, Wendy Osborne, et al.. (2023). Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Advances. 7(12). 2872–2883. 64 indexed citations
5.
Jacobson, Caron A., Javier Muñoz, Fang Sun, et al.. (2023). Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy. 30(1). 77.e1–77.e15. 47 indexed citations
6.
Sanderson, Robin, Shankara Paneesha, Piers Patten, et al.. (2023). CAR T treatment access and outcomes in patients with large B‐cell lymphoma according to ethnicity and socioeconomic deprivation. Hematological Oncology. 41(S2). 452–453.
7.
Eyre, Toby A., Mark Bishton, Rory McCulloch, et al.. (2023). Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline. British Journal of Haematology. 204(1). 108–126. 10 indexed citations
8.
9.
Boyle, Stephen, Robin Sanderson, Maeve O’Reilly, et al.. (2022). Improvement in Lymphoma CAR-T Outcomes over Time in the UK - CAR-T Learning Curve or Better Bridging?. Blood. 140(Supplement 1). 4649–4651. 1 indexed citations
10.
Kühnl, Andrea, Piers Patten, Deborah Yallop, et al.. (2022). P1169: ELEVATED CRP AT INFUSION OF AXICABTAGENE CILOLEUCEL PREDICTS HIGH-GRADE CAR-T TOXICITY AND OUTPERFORMS MORE COMPLEX SCORES. HemaSphere. 6. 1055–1056. 1 indexed citations
11.
O’Reilly, Maeve, Robin Sanderson, William Wilson, et al.. (2022). Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom. Blood. 140(Supplement 1). 7519–7521. 9 indexed citations
12.
Kühnl, Andrea, Malur Sudhanva, Victoria Metaxa, et al.. (2021). Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucel Treatment for Refractory Diffuse Large B Cell Lymphoma. HemaSphere. 5(3). e535–e535. 11 indexed citations
13.
Sanderson, Robin, Andrea Kühnl, Eleni Tholouli, et al.. (2021). CAR-T Toxicity Management and Steroid Use in High-Grade B-Cell Lymphoma: Impact on Real-World Survival Outcomes in the UK. Blood. 138(Supplement 1). 531–531. 6 indexed citations
14.
Kühnl, Andrea, G. Mikhaeel, Amy A. Kirkwood, et al.. (2021). Radiotherapy Bridging in Patients With R/R High-Grade Lymphoma Receiving CD19 CAR-T in the UK. International Journal of Radiation Oncology*Biology*Physics. 111(3). S130–S130. 5 indexed citations
15.
Kühnl, Andrea, Amy A. Kirkwood, Maeve O’Reilly, et al.. (2021). OUTCOME OF LARGE B‐CELL LYMPHOMA PATIENTS FAILING CD19 TARGETED CAR‐T THERAPY. Hematological Oncology. 39(S2). 5 indexed citations
16.
Potter, Victoria, Ruha Benjamin, Piers Patten, et al.. (2021). PH-0329 Feasibility and outcome of bridging RT pre CAR-T in DLBCL in one centre with a wide referral network. Radiotherapy and Oncology. 161. S241–S242. 2 indexed citations
17.
18.
19.
Sanderson, Robin, Peter Johnson, Anthony V. Moorman, et al.. (2006). Population-based demographic study of karyotypes in 1709 patients with adult Acute Myeloid Leukemia. Leukemia. 20(3). 444–450. 36 indexed citations
20.
Sanderson, Robin, et al.. (2004). The Distribution of the HIV Protease Inhibitor, Ritonavir, to the Brain, Cerebrospinal Fluid, and Choroid Plexuses of the Guinea Pig. Journal of Pharmacology and Experimental Therapeutics. 308(3). 912–920. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Núria Martínez‐Cibrián Breakdown of academic impact, for papers by Matthew L. Ulrickson Breakdown of academic impact, for papers by Maria A. V. Marzolini Breakdown of academic impact, for papers by Ana Cordeiro Breakdown of academic impact, for papers by Monalisa Ghosh Breakdown of academic impact, for papers by Patricia Steinert Breakdown of academic impact, for papers by Viktoria Blumenberg Breakdown of academic impact, for papers by Kathleen Ruehle Breakdown of academic impact, for papers by Xiaolu Long
Rankless by CCL
2026